Animal healthcare company Zoetis (ZTS) faces headwinds from companion animal product sales due to a competitive landscape, primarily from its key dermatology franchise and Simparica Trio. Moreover, Zoetis’ Convenia and Cerenia brands face heightened competition from generic brands.
The company is also dealing with lower sales from Librela, its monoclonal antibody (mAb) product for osteoarthritis (OA) pain in pets, due to some safety concerns regarding its usage. Solensia, another one of its OA medicines, has also come under fire. However, Librela has received the vote of confidence from the Veterinary Medicines Directorate in the U.K.